Content of ecstasy in the Netherlands: 1993-2008

Addiction

Volumn 104, Issue 12, 2009, Pages 2057-2066

  Vogels, Neeltje ^a   Brunt, Tibor M ^a   Rigter, Sander ^a   Van Dijk, Peter ^a   Vervaeke, Hylke ^a   Niesink, Raymond J M ^a  

^a NETHERLANDS INSTITUTE OF MENTAL HEALTH AND ADDICTION   (Netherlands)

Author keywords

DIMS; Ecstasy; MDMA; Monitor

Indexed keywords

3,4 METHYLENEDIOXYAMPHETAMINE; 3,4 METHYLENEDIOXYMETHAMPHETAMINE; AMPHETAMINE; CAFFEINE;

ARTICLE; CONTROLLED STUDY; DRUG DEPENDENCE; DRUG TRAFFIC; NETHERLANDS; RISK ASSESSMENT;

DRUG CONTAMINATION; HALLUCINOGENS; HUMANS; N-METHYL-3,4-METHYLENEDIOXYAMPHETAMINE; NETHERLANDS; TABLETS; TIME FACTORS;

EID: 70449427728     PISSN: 09652140     EISSN: 13600443     Source Type: Journal    
DOI: 10.1111/j.1360-0443.2009.02707.x     Document Type: Article

References (51)

1. Weir E. Raves: a review of the culture, the drugs and the prevention of harm. Can Med Assoc J 2000 162 : 1843 1848.
2. Forsyth A. J., Barnard M., McKeganey N. P. Musical preference as an indicator of adolescent drug use. Addiction 1997 92 : 1317 1325.
3. Pedersen W., Skrondal A. Ecstasy and new patterns of drug use: a normal population study. Addiction 1999 94 : 1695 1706.
4. Lenton S., Boys A., Norcross K. Raves, drugs and experience: drug use by a sample of people who attend raves in Western Australia. Addiction 1997 92 : 1327 1337.
5. European Monitoring Centre for Drugs and Drug Addiction (EMCDDA). Annual Report 2007: The State of the Drugs Problem in Europe. Lisbon : EMCDDA 2007.
6. M ter Bogt T. F., Engels R. C. 'Partying' hard: party style, motives for and effects of MDMA use at rave parties. Subst Use Misuse 2005 40 : 1479 1502.
7. Nichols D. E. Differences between the mechanism of action of MDMA, MBDB, and the classic hallucinogens. Identification of a new therapeutic class: entactogens. J Psychoact Drugs 1986 18 : 305 313.
8. Spruit I. P. Monitoring synthetic drug markets, trends, and public health. Subst Use Misuse 2001 36 : 23 47.
9. Gamma A., Jerome L., Liechti M. E., Sumnall H. R. Is ecstasy perceived to be safe? A critical survey. Drug Alcohol Depend 2005 77 : 185 193.
10. Patel M. M., Wright D. W., Ratcliff J. J., Miller M. A. Shedding new light on the 'safe' club drug: methylenedioxymethamphetamine (ecstasy)-related fatalities. Acad Emerg Med 2004 11 : 208 210.
11. Libiseller K., Pavlic M., Grubwieser P., Rabl W. Ecstasy - deadly risk even outside rave parties. Forensic Sci Int 2005 153 : 227 230.
12. Ben Abraham R., Szold O., Rudick V., Weinbroum A. A. 'Ecstasy' intoxication: life-threatening manifestations and resuscitative measures in the intensive care setting. Eur J Emerg Med 2003 10 : 309 313.
13. Henry J. A., Jeffreys K. J., Dawling S. Toxicity and deaths from 3,4-methylenedioxymethamphetamine ('ecstasy'). Lancet 1992 340 : 384 387.
14. Verschraagen M., Maes A., Ruiter B., Bosman I. J., Smink B. E., Lusthof K. J. Post-mortem cases involving amphetamine-based drugs in the Netherlands. Comparison with driving under the influence cases. Forensic Sci Int 2007 170 : 163 170.
15. De Letter E. A., Piette M. H., Lambert W. E., Cordonnier J. A. Amphetamines as potential inducers of fatalities: a review in the district of Ghent from 1976 to 2004. Med Sci Law 2006 46 : 37 65.
16. European Monitoring Centre for Drugs and Drug Addiction (EMCDDA). Annual Report 2006: Developments in Drug Use within Recreational Settings (Selected Issue 3). Lisbon : EMCDDA 2006.
17. Gowing L. R., Henry-Edwards S. M., Irvine R. J., Ali R. L. The health effects of ecstasy: a literature review. Drug Alcohol Rev 2002 21 : 53 63.
18. Hall A. P., Henry J. A. Acute toxic effects of 'Ecstasy' (MDMA) and related compounds: overview of pathophysiology and clinical management. Br J Anaesth 2006 96 : 678 685.
19. Burgess C., O'Donohoe A., Gill M. Agony and ecstasy: a review of MDMA effects and toxicity. Eur Psychiatry 2000 15 : 287 294.
20. Cole J. C., Sumnall H. R. Altered states: the clinical effects of Ecstasy. Pharmacol Ther 2003 98 : 35 58.
21. Parrott A. C. Human research on MDMA (3,4-methylene- dioxymethamphetamine) neurotoxicity: cognitive and behavioural indices of change. Neuropsychobiology 2000 42 : 17 24.
22. McCann U. D., Eligulashvili V., Ricaurte G. A. (+/-)3,4- Methylenedioxymethamphetamine ('Ecstasy')-induced serotonin neurotoxicity: clinical studies. Neuropsychobiology 2000 42 : 11 6.
23. Ricaurte G. A., Yuan J., McCann U. D. (+/-)3,4- Methylenedioxymethamphetamine ('Ecstasy')-induced serotonin neurotoxicity: studies in animals. Neuropsychobiology 2000 42 : 5 10.
24. Schilt T., de Win M. M., Koeter M., Jager G., Korf D. J., van den Brink W. et al. Cognition in novice ecstasy users with minimal exposure to other drugs: a prospective cohort study. Arch Gen Psychiatry 2007 64 : 728 736.
25. Wareing M., Fisk J. E., Murphy P. N. Working memory deficits in current and previous users of MDMA ('ecstasy'). Br J Psychol 2000 91 : 181 188.
26. Reneman L., de Win M. M., van den B. W., Booij J., den Heeten G. J. Neuroimaging findings with MDMA/ecstasy: technical aspects, conceptual issues and future prospects. J Psychopharmacol 2006 20 : 164 175.
27. Gouzoulis-Mayfrank E., Daumann J. Neurotoxicity of methylenedioxyamphetamines (MDMA; ecstasy) in humans: how strong is the evidence for persistent brain damage? Addiction 2006 101 : 348 361.
28. Thomasius R., Zapletalova P., Petersen K., Buchert R., Andresen B., Wartberg L. et al. Mood, cognition and serotonin transporter availability in current and former ecstasy (MDMA) users: the longitudinal perspective. J Psychopharmacol 2006 20 : 211 225.
29. Wolff K., Hay A. W., Sherlock K., Conner M. Contents of 'ecstasy'. Lancet 1995 346 : 1100 1101.
30. Giraudon I., Bello P. Y. Monitoring ecstasy content in France: results from the National Surveillance System 1999-2004. Subst Use Misuse 2007 42 : 1567 1578.
31. Camilleri A. M., Caldicott D. Underground pill testing, down under. Forensic Sci Int 2005 151 : 53 8.
32. Johnston J., Barratt M. J., Fry C. L., Kinner S., Stoove M., Degenhardt L. et al. A survey of regular ecstasy users' knowledge and practices around determining pill content and purity: implications for policy and practice. Int J Drug Policy 2006 17 : 464 472.
33. Kenyon S. L., Ramsey J. D., Lee T., Johnston A., Holt D. W. Analysis for identification in amnesty bin samples from dance venues. Ther Drug Monit 2005 27 : 793 798.
34. Sherlock K., Wolff K., Hay A. W., Conner M. Analysis of illicit ecstasy tablets: implications for clinical management in the accident and emergency department. J Accid Emerg Med 1999 16 : 194 197.
35. Carter N., Rutty G. N., Milroy C. M., Forrest A. R. Deaths associated with MBDB misuse. Int J Legal Med 2000 113 : 168 170.
36. Martin T. L. Three cases of fatal paramethoxyamphetamine overdose. J Anal Toxicol 2001 25 : 649 651.
37. Kraner J. C., McCoy D. J., Evans M. A., Evans L. E., Sweeney B. J. Fatalities caused by the MDMA-related drug paramethoxyamphetamine (PMA). J Anal Toxicol 2001 25 : 645 648.
38. Caldicott D. G., Edwards N. A., Kruys A., Kirkbride K. P., Sims D. N., Byard R. W. et al. Dancing with 'death': p-methoxyamphetamine overdose and its acute management. J Toxicol Clin Toxicol 2003 41 : 143 154.
39. Refstad S. Paramethoxyamphetamine (PMA) poisoning; a 'party drug' with lethal effects. Acta Anaesthesiol Scand 2003 47 : 1298 1299.
40. Winstock A. R., Wolff K., Ramsey J. 4-MTA: a new synthetic drug on the dance scene. Drug Alcohol Depend 2002 67 : 111 115.
41. De Letter E. A., Coopman V. A., Cordonnier J. A., Piette M. H. One fatal and seven non-fatal cases of 4-methylthioamphetamine (4-MTA) intoxication: clinico-pathological findings. Int J Legal Med 2001 114 : 352 356.
42. O'Neal C. L., Crouch D. J., Fatah A. A. Validation of twelve chemical spot tests for the detection of drugs of abuse. Forensic Sci Int 2000 109 : 189 201.
43. Jeffrey W. Colour tests. In : Moffat A. C., Osselton M. D., Widdop B., editors. Clarke's Analysis of Drugs and Poisons. London : Pharmaceutical Press 2003, p. 279 300.
44. Parrott A. C. Is ecstasy MDMA? A review of the proportion of ecstasy tablets containing MDMA, their dosage levels, and the changing perceptions of purity. Psychopharmacology (Berl) 2004 173 : 234 241.
45. Bossong M., Brunt T., Van Dijk J., Rigter S., Hoek J., Goldschmidt H. et al. mCPP: an undesired addition to the ecstasy market. J Psychopharmacol 2009 in press.
46. European Monitoring Centre for Drugs and Drug Addiction (EMCDDA). Risk Assessment Report of a New Psychoactive Substance: 1-Benzylpiperazine (BZP). Lisbon : EMCDDA 2007.
47. Johnstone A. C., Lea R. A., Brennan K. A., Schenk S., Kennedy M. A., Fitzmaurice P. S. Benzylpiperazine: a drug of abuse? J Psychopharmacol 2007 21 : 888 894.
48. Cole J. C., Bailey M., Sumnall H. R., Wagstaff G. F., King L. A. The content of ecstasy tablets: implications for the study of their long-term effects. Addiction 2002 97 : 1531 1536.
49. Ramsey J. D., Butcher M. A., Murphy M. F., Lee T., Johnston A., Holt D. W. A new method to monitor drugs at dance venues. BMJ 2001 323 : 603.
50. Tanner-Smith E. E. Pharmacological content of tablets sold as 'ecstasy': results from an online testing service. Drug Alcohol Depend 2006 83 : 247 254.
51. Benschop A., Rabes M., Korf D. J. Pill Testing - Ecstasy & Prevention. Amsterdam : Rozenberg Publishers 2002.